Clinical Trials
5 trialsNCT05428969 2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2 Active not recruiting
NCT07460986 2026-03-10
BEXAR
MedSIR
Phase 1/2 Not yet recruiting
NCT03733990 2025-04-02
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Faron Pharmaceuticals Ltd
Phase 1/2 Completed
NCT05171062 2023-07-20
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT05104905 2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2 Withdrawn